Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial

References

• Bonhomme J, Shim RS, Gooden R, Tyus D, Rust G. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options. J Natl Med Assoc 2012; 104:342–50.
   PubMed Web of Science ®Google Scholar
• Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014; 109:79–87.
   PubMed Web of Science ®Google Scholar
• Gunderson EW, Fiellin DA. Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches? CNS Drugs 2008; 22:99–111.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med 2014; 370:2063–6.
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.
   Google Scholar
• Nielsen S, Hillhouse M, Weiss RD, et al. The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample. Am J Addict 2014; 23:343–8.
   PubMed Web of Science ®Google Scholar
• Hillhouse M, Canamar CP, Ling W. Predictors of outcome after short-term stabilization with buprenorphine. J Subst Abuse Treat 2013; 44:336–42.
   PubMed Web of Science ®Google Scholar
• Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med 2009; 24:226–32.
   PubMed Web of Science ®Google Scholar
• Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend 2007; 90:261–9.
   PubMed Web of Science ®Google Scholar
• Strain EC, Harrison JA, Bigelow GE. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther 2011; 89:443–9.
   PubMed Web of Science ®Google Scholar
• Strain EC, Walsh SL, Bigelow GE. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacol (Berl) 2002; 159:161–6.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Chausmer AE, Strain EC, Bigelow GE. Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacol (Berl) 2008; 196:143–55.
   PubMed Web of Science ®Google Scholar
• Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs 2009; 69:577–607.
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349:949–58.
   PubMed Web of Science ®Google Scholar
• Apelt SM, Scherbaum N, Golz J, Backmund M, Soyka M. Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care. Pharmacopsych 2013; 46:94–107.
   PubMed Web of Science ®Google Scholar
• Zubsolv (package insert). Morristown, NJ: Orexo US, Inc., 2015.
   Google Scholar
• Fischer A, Jonsson M, Hjelmstrom P. Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers. Drug Dev Ind Pharm 2015; 41:79–84.
   PubMed Web of Science ®Google Scholar
• Fischer A, Johansson K, Gruden S. Zubsolv®: a novel sublingual tablet with improved bioavailability of buprenorphine for treatment of opioid dependence (poster). Presented at: Annual Conference of the Association for Medical Education and Research in Substance Abuse, San Francisco, CA, November 6–7, 2014.
   Google Scholar
• Suboxone (package insert). Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc., 2014.
   Google Scholar
• Gunderson EW, Sumner M. Efficacy of buprenorphine/naloxone rapidly dissolving sublingual tablets (BNX-RDT) after switching from BNX sublingual film. J Addict Med 2016; 10:122–8.
   PubMed Web of Science ®Google Scholar
• Webster L, Helmstrom P, Sumner M. Assessing buprenorphine/naloxone efficacy during induction therapy in opioid-dependent patients: what is the ideal measure? (poster). Presented at: Annual Meeting and Symposium of the American Academy of Addiction Psychiatry, Aventura, FL, December 4–7, 2014.
   Google Scholar
• Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007; 5:146–50.
   PubMed Web of Science ®Google Scholar
• Amass L, Pukeleviciene V, Subata E, et al. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. Addiction 2012; 107:142–51.
   PubMed Web of Science ®Google Scholar
• Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003; 35:253–9.
   PubMed Web of Science ®Google Scholar
• Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987; 13:293–308.
   PubMed Web of Science ®Google Scholar
• Gunderson EW, Hjelmstrom P, Sumner M. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial. Clin Ther 2015; 37:2244–55.
   PubMed Web of Science ®Google Scholar
• Gunderson EW, Wang XQ, Fiellin DA, Bryan B, Levin FR. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav 2010; 35:537–40.
   PubMed Web of Science ®Google Scholar
• Doran C, Holmes J, Ladewig D, Ling W. Buprenorphine induction and stabilisation in the treatment of opiate dependence. Heroin Addict Relat Clin Probl 2005; 7:18.
   Google Scholar
• Gunderson EW, Levin FR, Rombone MM, Vosburg SK, Kleber HD. Improving temporal efficiency of outpatient buprenorphine induction. Am J Addict 2011; 20:397–404.
   PubMed Web of Science ®Google Scholar
• Casadonte P. PCSS guidance. http://pcssmat.org/ (accessed May 2, 2016).
   Google Scholar